海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

交易中 12-18 14:34:24

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":5.96,"timestamp":1766039664000,"preClose":5.83,"halted":0,"volume":12942900,"delay":0,"changeRate":0.0223,"floatShares":1616000000,"shares":1619000000,"eps":-0.207,"marketStatus":"交易中","change":0.13,"latestTime":"12-18 14:34:24","open":5.87,"high":6.04,"low":5.84,"amount":76834400,"amplitude":0.0343,"askPrice":5.96,"askSize":1074,"bidPrice":5.95,"bidSize":115,"shortable":0,"etf":0,"ttmEps":-0.207,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766041200000},"marketStatusCode":2,"adr":0,"adjPreClose":5.83,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":6.41,"lowLimit":5.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":1.84,"roa":"--","roe":"0.14%","epsLYR":-0.21,"committee":-0.387832,"marketValue":9648000000,"turnoverRate":0.008,"status":0,"floatMarketCap":9630000000},"requestUrl":"/m/hq/s/002099","defaultTab":"news","newsList":[{"id":"2592995768","title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995768","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995768?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:58","pubTimestamp":1765965522,"startTime":"0","endTime":"0","summary":"公告显示，NWRD08注射液是我国自主研发的首个针对HPV16/18阳性宫颈高级别鳞状上皮内病变进入Ⅱ期临床阶段的新一代治疗性核酸药物，其通过激活特异性T细胞免疫清除感染细胞。与预防性HPV疫苗不同，其专门针对已感染HPV并出现相关病变的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)：NWRD08注射液完成Ⅱ期临床首例受试者入组","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002099","BK0239","BK0192","BK0077","BK0028"],"gpt_icon":0},{"id":"2590567748","title":"海翔药业：截止12月10日公司股东人数为27495人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590567748?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:07","pubTimestamp":1765436843,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：截至12月10日股东人数为多少？海翔药业回复：您好，截止12月10日公司股东人数为27495人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0192","BK0188","BK0239","002099"],"gpt_icon":0},{"id":"2590464903","title":"海翔药业：公司目前经营情况正常且现金流健康稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2590464903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590464903?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:51","pubTimestamp":1765284677,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：1，公司目前现金流情况，后续并购项目的考虑？2，公司行业整体情况以及公司在手订单情况？请详告。海翔药业回复：您好，公司目前经营情况正常且现金流健康稳健，未来如有并购相关计划，将严格按照相关法律法规及时履行信息披露义务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159399","BK0188","BK0239","BK0192","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2590316879","title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316879","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316879?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:18","pubTimestamp":1765268289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业(002099.SZ)公告，公司与国科大杭州高等研究院(简称“杭高院”)签署了《共建先进合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料的开发与工业化等，合作总金额5000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海翔药业(002099.SZ)拟与杭高院共建先进合成技术产业研究院","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0077","002099","BK0192","BK0188"],"gpt_icon":0},{"id":"2589338424","title":"海翔药业：生产基地主要分布在台州地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338424?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181715,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司目前的产能分布及产能利用率情况？海翔药业回复：您好，公司目前生产基地主要分布在台州地区，当前生产经营活动正常有序，在手订单储备与客户需求节奏相匹配，产能利用率维持在合理水平。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800015519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0192","002099","BK0188","BK0077","BK0239"],"gpt_icon":0},{"id":"2588742084","title":"海翔药业：截止11月28日公司股东人数为27406人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588742084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588742084?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:57","pubTimestamp":1764575835,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月28日公司的股东人数为多少？海翔药业回复：您好，截止11月28日公司股东人数为27406人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100013550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0028","BK0077","BK0188","002099"],"gpt_icon":0},{"id":"2586023425","title":"海翔药业：参投基金持有天兵科技1.352%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586023425","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586023425?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:33","pubTimestamp":1764145990,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业11月26日在投资者关系平台上答复投资者关心的问题。海翔药业回复：您好，公司参投的寓鑫基金持有天兵科技1.352%股权，该基金投资项目还涉及航天航空材料、金属新材料、医药研发、高端设备制造、芯片制造等领域。此外公司投资设立的产业基金北京国信海翔参投了部分创新药项目，涉及HPV感染及肝癌治疗性疫苗、TCR-T细胞治疗、重组巴曲酶等领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600021931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0028","BK0239","BK0188","BK0192","BK0077"],"gpt_icon":0},{"id":"2585113335","title":"海翔药业：截止11月20日公司股东人数为27726人","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113335?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:36","pubTimestamp":1763714174,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月20日公司股东人数为多少？海翔药业回复：您好，截止11月20日公司股东人数为27726人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100021097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","BK0188","BK0192","002099"],"gpt_icon":0},{"id":"2584095654","title":"海翔药业（002099）披露2025年第一次临时股东大会决议公告，11月18日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584095654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584095654?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:43","pubTimestamp":1763476998,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，海翔药业报收于6.31元，较前一交易日下跌0.94%，最新总市值为102.14亿元。近日，浙江海翔药业股份有限公司发布2025年第一次临时股东大会决议公告。公告显示，公司于2025年11月18日召开2025年第一次临时股东大会，审议通过了董事会换届选举议案，选举王扬超、许国睿、姚冰、陈光顺、陈方琪为第八届董事会非独立董事，俞永平、钱建民、梁超为独立董事。会议召集召开程序合法，表决结果有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","BK0188","BK0192","002099"],"gpt_icon":0},{"id":"2583258099","title":"海翔药业：截止11月10日股东人数为28546人","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583258099?lang=zh_cn&edition=full","pubTime":"2025-11-13 08:57","pubTimestamp":1762995426,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：截至11月10日公司的股东人数为多少？海翔药业回复：您好，截止11月10日公司股东人数为28546人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300008341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0192","BK0028","BK0239","002099","BK0077"],"gpt_icon":0},{"id":"2581081137","title":"股市必读：海翔药业（002099）11月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081137","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081137?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:07","pubTimestamp":1762387620,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2025年11月5日收盘，海翔药业报收于6.34元，上涨1.6%，换手率2.15%，成交量34.71万手，成交额2.18亿元。　　来自交易信息汇总：11月5日主力资金净流入691.55万元，显示主力对海翔药业股票的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251106/31771339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0077","BK0239","BK0028","BK0192","002099"],"gpt_icon":0},{"id":"2581749227","title":"海翔药业：截止10月31日公司股东人数为27574人","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581749227?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:33","pubTimestamp":1762331591,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)11月05日在投资者关系平台上答复投资者关心的问题。投资者提问：截至10月30日公司的股东人数为多少？海翔药业回复：您好，截止10月31日公司股东人数为27574人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500027637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0192","BK0077","002099","BK0028"],"gpt_icon":0},{"id":"2580694722","title":"11月3日海翔药业（002099）涨停分析：治理优化、产品提价、研发驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2580694722","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580694722?lang=zh_cn&edition=full","pubTime":"2025-11-03 15:31","pubTimestamp":1762155107,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业11月3日涨停收盘，收盘价6.31元。今日海翔药业涨停的可能因素有：1. 公司治理结构优化取得进展，包括董事会换届、管理制度修订及股份回购计划完成87%，提振市场信心；2. 核心产品克林霉素价格回升及培南系列价格企稳，叠加染料业务扭亏为盈，推动毛利率改善；3. 疫苗研发合作项目持续推进，联苯双酯原料药生产销售及肝胆领域在研项目强化医药业务布局；4. 化学制药板块整体活跃形成联动效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300015087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002099","BK0192","BK0077","BK0239"],"gpt_icon":0},{"id":"2579155736","title":"股市必读：海翔药业三季报 - 第三季度单季净利润同比增长73.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579155736","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579155736?lang=zh_cn&edition=full","pubTime":"2025-10-30 07:50","pubTimestamp":1761781835,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，海翔药业报收于5.67元，下跌0.7%，换手率0.63%，成交量10.14万手，成交额5723.37万元。来自业绩披露要点：2025年第三季度主营收入同比增长8.82%，但单季度归母净利润仍为亏损680.34万元。来自公司公告汇总：监事会审议通过《2025年第三季度报告》及部分募投项目延期议案，项目延期不涉及实施主体和募集资金用途变更。股本股东变化股东户数变动近日海翔药业披露，截至2025年10月20日公司股东户数为2.77万户，较10月10日增加209.0户，增幅为0.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000007751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099"],"gpt_icon":0},{"id":"2579995513","title":"图解海翔药业三季报：第三季度单季净利润同比增长73.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579995513","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579995513?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:01","pubTimestamp":1761678085,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业2025年三季报显示，公司主营收入13.67亿元，同比下降5.39%；归母净利润729.03万元，同比下降39.15%；扣非净利润501.05万元，同比下降72.75%；其中2025年第三季度，公司单季度主营收入4.41亿元，同比上升8.82%；单季度归母净利润-680.34万元，同比上升73.96%；单季度扣非净利润-1427.28万元，同比下降14.53%；负债率29.77%，投资收益1018.82万元，财务费用-948.06万元，毛利率25.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099"],"gpt_icon":0},{"id":"2578963041","title":"海翔药业（002099）披露部分募投项目延期公告，10月28日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578963041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578963041?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:22","pubTimestamp":1761661331,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，海翔药业报收于5.71元，较前一交易日上涨0.35%，最新总市值为92.43亿元。该股当日开盘5.7元，最高5.76元，最低5.67元，成交额达4908.75万元，换手率为0.53%。公司近日发布公告称，第七届监事会第十次会议于2025年10月27日以通讯表决方式召开，会议审议通过《关于部分募投项目延期的议案》。该项议案已获监事会全票通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0192","002099","BK0028","BK0239"],"gpt_icon":0},{"id":"2577844999","title":"海翔药业：截止10月20日公司股东人数为27682人","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844999","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577844999?lang=zh_cn&edition=full","pubTime":"2025-10-21 15:45","pubTimestamp":1761032726,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截止10月20日公司的股东人数为多少？海翔药业回复：您好，截止10月20日公司股东人数为27682人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100020104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","BK0188","BK0192","002099"],"gpt_icon":0},{"id":"2575410963","title":"股市必读：海翔药业（002099）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575410963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575410963?lang=zh_cn&edition=full","pubTime":"2025-10-13 04:54","pubTimestamp":1760302453,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，海翔药业报收于5.85元，上涨0.0%，换手率0.85%，成交量13.67万手，成交额8057.11万元。来自：截至2025年9月30日，海翔药业已累计回购股份4,410,000股，占公司总股本的0.27%，成交总金额达26,090,960.52元。回购资金总额不低于15,000万元（含），不超过30,000万元（含），回购价格不超过7.46元/股（含），实施期限为董事会审议通过之日起12个月内。公司回购行为符合相关法规及既定方案。后续将根据市场情况继续实施回购，并按规定履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300001666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002099","BK0192","BK0077","BK0239"],"gpt_icon":0},{"id":"2574166490","title":"海翔药业（002099）披露股份回购进展情况，10月09日股价上涨2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574166490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574166490?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:35","pubTimestamp":1760020520,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘，海翔药业报收于5.85元，较前一交易日上涨2.99%，最新总市值为94.69亿元。公司近日发布公告，披露了关于股份回购的进展情况。公司回购行为符合相关法规及既定方案。后续将根据市场情况继续实施回购，并按规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900034576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0077","BK0192","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2569728331","title":"海翔药业：截止9月19日公司股东人数为26641人","url":"https://stock-news.laohu8.com/highlight/detail?id=2569728331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569728331?lang=zh_cn&edition=full","pubTime":"2025-09-24 08:55","pubTimestamp":1758675312,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，截至9月19日公司股东人数为多少？海翔药业回复：您好，截止9月19日公司股东人数为26641人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400008792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002099","BK0077","BK0192","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766039665709,"stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0848},{"period":"3month","weight":-0.0833},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.0448},{"period":"ytd","weight":0.1298}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27495人(较上一季度增加0.32%)","perCapita":"58763股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是医药及染料全产业链业务。公司的主要产品是原料药及医药中间体、合同定制业务、制剂、染料及染颜料中间体。公司已承担完成国家级项目13项，省级项目35项，拥有国内发明专利61项、PCT专利4项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}